Chul Kim, MD

The segment discusses consistency of re-biopsy being performed in the clinical setting along with key barriers to obtaining biopsies for patients.

The segment introduces second-line sequencing, reviewing NCCN preferred options after frontline therapy.

This segment covers central nervous system (CNS) involvement in EGFR-mutated NSCLC.

This segment turns from trial data to real-world practice, examining how quickly community oncology is adopting frontline combination regimens for EGFR-mutated NSCLC.

This segment interprets the TOP study findings and their practice implications.

This opening segment introduces an OncLive program built around ASCO data on risk-guided treatment intensification and sequencing in EGFR-mutated advanced non-small cell lung cancer (NSCLC).